Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339748 | 0.82 | NAPRT (0.43) | TAAR1EPHX1MAPTCYP1A2CYP3A4 | |
| SCHEMBL296132 | 0.80 | NPC1 (0.50) | PRKCIKDM4EL3MBTL1LMNAALDH1A1 | |
| SCHEMBL29396801 | 0.80 | NPC1 (0.50) | PRKCIKDM4EL3MBTL1LMNAALDH1A1 | |
| SCHEMBL1849484 | 0.71 | CYP1A2 (0.45) | KDM4EMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28365470 | 0.71 | CYP1A2 (0.45) | KDM4EMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28365468 | 0.71 | CYP1A2 (0.45) | KDM4EMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1091229 | 0.71 | CTSD (0.50) | MDM2KDM4EL3MBTL1MAPKAPK2RAD52 | |
| Isonicotinic Acid SCHEMBL27942386 | 0.68 | NAPRT (0.74) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C9 | |
| Bicarbonate SCHEMBL23093808 | 0.67 | MDM2 (0.54) | MDM2TAAR1JAK2TYK2KDM4E | |
| SCHEMBL334744 | 0.67 | L3MBTL1 (0.72) | MDM2TAAR1KDM4EL3MBTL1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022197-A1 | METHODS OF REVERSING TICAGRELOR ACTIVITY | SFJ PHARMA X INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025129010-A1 | METHODS OF STRUCTURE DETERMINATION USING ANTIBODIES | GENENTECH, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240350653-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | JOINT STOCK COMPANY GENERIUM (RU) | 2024-10-24 | — | — | US | disclosed |
| WO-2024177535-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE PROPHYLAXIS AND TREATMENT OF A LYSOSOMAL ENZYME DEFICIENCY IN A SUBJECT WITH MUCOPOLYSACCHARIDOSIS TYPE II | Акционерное общество "ГЕНЕРИУМ" | 2024-08-29 | — | — | WO | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4389772-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | Joint-Stock Company "Generium" (RU) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023022629-A1 | TARGETED DELIVERY OF THERAPEUTIC ENZYMES | Акционерное общество "ГЕНЕРИУМ" | 2023-02-23 | — | — | WO | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| EP-3089996-B1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | HOFFMANN LA ROCHE (CH) | 2021-07-28 | — | — | EP | disclosed |
| EP-2661282-A1 | A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130280279-A1 | PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | HOFFMANN LA ROCHE (US) | 2013-10-24 | — | — | US | disclosed |
| US-8268784-B2 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012093068-A1 | A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100137223-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | CONDE-KNAPE KARIN | 2010-06-03 | — | — | US | disclosed |
| US-7642244-B2 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1962959-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065808-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | CONDE-KNAPE KARIN | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | MDM2 4715/4885TAAR1 134/4885JAK2 399/4885 |
| US-20100137223-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | NPY2R, NPY1R, NPY5R | MDM2 4220/4885TAAR1 172/4885JAK2 633/4885 |
| US-20260022197-A1 | METHODS OF REVERSING TICAGRELOR ACTIVITY | P2RY12, P2RY13, PTAFR | MDM2 2293/4885TAAR1 3379/4885JAK2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.